8-K: Iovance Biotherapeutics Prices $211 Million Stock Offering to Fund AMTAGVI Launch and Clinical Programs

Iovance Biotherapeutics has announced the pricing of a $211 million underwritten offering of common stock to support the commercial launch of AMTAGVI and fund ongoing clinical programs.

Summary

• Iovance Biotherapeutics has priced an underwritten offering of 23,014,000 shares of its common stock at $9.15 per share.
• The gross proceeds from the offering are expected to be approximately $211 million before deducting underwriting discounts and other expenses.
• The company estimates net proceeds of approximately $197.1 million after deducting underwriting discounts, commissions, and estimated offering expenses.
• The offering is expected to close on or about February 22, 2024, subject to customary closing conditions.
• Iovance intends to use the net proceeds to support the commercial launch of AMTAGVI, fund ongoing clinical programs, continue the development of pipeline candidates, and for other general corporate purposes.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the offering dilutes existing shareholders, it provides necessary capital for the company's growth and commercialization efforts. The involvement of reputable underwriters also adds a positive note.

Positives

• The capital raise will provide significant funding for the commercial launch of AMTAGVI.
• The funds will support ongoing clinical programs, including the NSCLC registration-directed study and the frontline advanced melanoma Phase 3 trial.
• The offering will enable the continued development of the company's pipeline candidates.
• The company has secured underwriting from Jefferies LLC, Barclays Capital Inc., and Goldman Sachs & Co. LLC.

Negatives

• The offering will dilute existing shareholders' ownership.
• The company will incur underwriting discounts, commissions, and other offering expenses, reducing the net proceeds.
• The offering price of $9.15 per share is below the market price prior to the announcement.

Risks

• The offering is subject to customary closing conditions, and there is a risk that the closing may not occur.
• Market conditions could affect the completion of the offering or the anticipated terms.
• The company's future performance is subject to risks and uncertainties inherent in its business.
• There is a risk that the company may not be able to achieve its goals with the funds raised.

Future Outlook

The company intends to use the net proceeds from the offering to support the commercial launch of AMTAGVI, fund ongoing clinical programs, continue the development of its pipeline candidates, and for other general corporate purposes. The company is also committed to continuous innovation in cell therapy, including gene-edited cell therapy.

Management Comments

• Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer.
• We are pioneering a transformational approach to cure cancer by harnessing the human immune systems ability to recognize and destroy diverse cancer cells in each patient.

Industry Context

This offering is part of a broader trend in the biotechnology industry where companies raise capital to fund research, development, and commercialization of new therapies. Iovance's focus on TIL therapy positions it in a competitive but promising area of cancer treatment.

Comparison to Industry Standards

• The size of the offering is comparable to other biotech companies raising capital for commercialization and clinical trials.
• The use of proceeds is typical for a company at Iovance's stage, focusing on product launch and clinical development.
• The involvement of major investment banks like Jefferies, Barclays, and Goldman Sachs is standard for offerings of this size and nature.
• Comparable companies that have recently raised capital include Xometry, Inc. which raised $300 million in a convertible note offering and Amylyx Pharmaceuticals, Inc. which raised $190 million in a public offering.

Stakeholder Impact

• Shareholders will experience dilution of their ownership due to the issuance of new shares.
• The company's employees will benefit from the increased financial stability and resources for growth.
• Patients will potentially benefit from the commercial launch of AMTAGVI and the development of new therapies.
• The company's creditors will be impacted by the increased financial stability of the company.

Next Steps

• The company will proceed with the closing of the offering, expected on or about February 22, 2024.
• The company will use the net proceeds to support the commercial launch of AMTAGVI, fund ongoing clinical programs, and continue the development of its pipeline candidates.
• The company will continue to monitor market conditions and make necessary filings with the SEC.

Key Dates

Keywords

Iovance Biotherapeutics, stock offering, capital raise, AMTAGVI, clinical programs, TIL therapy, biotechnology, Jefferies LLC, Barclays Capital Inc., Goldman Sachs & Co. LLC